Odontoprev S.A. stock (BRODPVACNOR4): valuation focus after Q1 2026 earnings

Odontoprev S.A., whose shares trade on the B3 exchange in São Paulo under the ticker ODPV3, has stayed on investors radar following the publication of its first-quarter 2026 results in May and a generally stable share-price performance on the Brazilian market.

According to the companys investor-relations information and recent coverage, Odontoprev reported its Q1 2026 numbers in early May 2026, providing updated insights into its revenue base, profitability and cash generation as Brazil remains its primary geography for private dental plans.

The stock traded in its regular session on B3 in recent days in Brazilian real, offering domestic investors direct exposure to the countrys dental-benefits segment, while also appearing on the radar of international market-data services through its ISIN BRODPVACNOR4.

For German-speaking investors accessing Brazilian equities via local trading venues, Odontoprev can typically be traded over-the-counter, though liquidity and spreads tend to be driven mainly by the underlying volume on B3 in São Paulo rather than in Europe.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Odontoprev S.A.: core business model

Odontoprev operates as a specialized provider of dental benefit plans in Brazil, generating most of its income from recurring premiums paid by corporate clients, financial-institution partners and individual policyholders.

Valuation metrics and multiples for Odontoprev S.A.

With the Q1 2026 results filed and discussed on an earnings call in May 2026, attention has turned to how the market is valuing Odontoprev relative to its earnings and cash flows, using metrics such as price-earnings ratios, enterprise-value-to-EBITDA multiples and dividend yields.

Public market-data aggregators that track Brazilian equities show that Odontoprev is followed as part of the countrys listed healthcare and insurance universe, where investors often compare its valuation to peers in health plans and broader financial services, while also considering the companys track record of profitability and shareholder distributions.

Conclusion

The latest Q1 2026 report keeps Odontoprev in focus on the B3 exchange, as investors digest the performance of its Brazilian dental-benefits franchise and gauge its earnings resilience in the domestic market.

Against that backdrop, valuation metrics such as earnings multiples and dividend yields remain central for market participants comparing the stock with Brazils broader healthcare and insurance sector, even though detailed numbers can vary across data providers.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.